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Abstract: Serratia marcescens (S. marcescens) has become an important nosocomial pathogens and increased resistant 
isolates were reported. The current study evaluates the impact of an alternate energy medicine i.e. Mr. Trivedi’s biofield energy 
treatment on S. marcescens for changes in sensitivity pattern of antimicrobial, biochemical characteristics, and biotype number. 
S. marcescens cells were procured from MicroBioLogics Inc., USA in sealed pack bearing the American Type Culture 
Collection (ATCC 13880) number and divided into two groups, Group (Gr.) I: control and Gr. II: treated. Gr. II was further 
subdivided into two sub-groups, Gr. IIA and Gr. IIB. Gr. IIA was analyzed on day 10, while Gr. IIB was stored and analyzed 
on day 159 (Study I). After retreatment on day 159, the sample (Study II) was divided into three separate tubes as first, second 
and third tube, which were analyzed on day 5, 10 and 15 respectively. All experimental parameters were studied using the 
automated MicroScan Walk-Away
®
 system. Antimicrobial susceptibility results showed that 42.85% of tested antimicrobials 
results in altered sensitivity pattern, while decreased minimum inhibitory concentration values in 40.62% tested antimicrobials 
as compared to the control after biofield treatment on S. marcescens. The biochemical study showed that 12 out of 33 tested 
biochemicals (36.36%) were reported for alteration of biochemical reactions pattern as compared to the control. Biotype study 
showed an alteration in biotype number in all the experimental treated groups as compared to the control. These results 
suggested that biofield energy treatment has a significant impact on S. marcescens. Overall, it is expected that Mr. Trivedi’s 
biofield energy treatment as an integrative medicine could be better therapy approach in near future. 
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1. Introduction 
Serratia marcescens (S. marcescens), is a Gram-negative 
bacillus, and member of the genus Serratia is classified as 
the member of Enterobacteriaceae. Most of the reported 
species of Serratia are associated with hospital acquired 
human infection from the last two decades [1]. Serratia spp. 
are motile, non-endospore forming rods shaped usually 
isolated from bloodstream and wound sites or from 
respiratory and urinary sites. Most common and best known 
clinical species are S. marcescens, S. liquefaciens and S. 
odorifera [2]. Among them, S. marcescens is the most 
common and the most important human pathogen in every 
conceivable kind of infections such as respiratory tract 
infection, urinary tract infection (UTI), septicaemia, 
meningitis and wound infections [3-5]. It is also reported that 
S. marcescens causes ocular infections, and show high 
incidence of contact lens-related keratitis [6]. However, it is 
also associated with infective endocarditis, which usually 
affects the left side of the heart. Hospital acquired 
endocarditis due to S. marcescens is usually an exogenous 
infection related with cardiac surgery [7]. It is noticeable that 
the drug resistance pattern in Serratia spp. may vary even 
within a short period, due to continuous use of antibiotics. 
Besides, due to the several associated side effects of 
antibiotics, the use of integrative approaches to health and 
wellness has grown within hospital care settings. Researchers 
are currently exploring the potential benefits of integrative 
energy medicine in a variety of situations to promote the 
health and wellness of individuals across the world. The 
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practice of energy healing therapies involve an alteration in 
consciousness states including metaphysical, magnetic, 
psychological, and social processes, which produce a 
beneficial effect upon the energy field of the patient. 
The energy medicine is one of the major categories of 
complementary and alternative medicine (CAM). Energy 
healing therapies (putative energy fields) are very popular in 
health care systems [8], and are defined under the 
subcategory of energy therapies by National Center for 
Complementary and Alternative Medicine (NCCAM) [9]. 
These therapies include human energy therapies, 
bioelectromagnetic therapy, magnet therapy, acupuncture, 
electrodermal therapy, homeopathy, and phototherapy that 
include low-level energy field interactions. The possible 
impact of biofield energy may be as it changes the 
conformation of biomolecules, may act directly on molecular 
structure, or it may transfer bioinformation via small energy 
signals [10]. Biofield treatment refers to a group of energy 
therapy that affects people’s health and wellbeing by 
interacting with their biofield [11]. The human body emits 
the electromagnetic waves in the form of bio-photons and 
moving electric charged particles (ions, cell, molecule etc.) 
surround the body produce magnetic fields. Thus, human has 
the ability to harness the energy from the environment or 
universe and can transmit into any living or nonliving 
object(s) around the Globe. Specific environmental 
frequencies can be absorbed by biomolecules, and 
responding into the useful way that is called biofield energy 
and the process is known as biofield treatment. Mr. Trivedi’s 
unique biofield energy is also known as The Trivedi effect
®
, 
which has been effectively reported in the field of materials 
science research [12-14], agricultural research [15-18], and 
microbiology research [19, 20].  
Considering the importance of increasing integrative 
medicine therapies in health care settings, and clinical 
importance of S. marcescens, the impact of biofield energy 
therapy was evaluated with respect to antibiogram, 
biochemical study, and biotype number.  
2. Materials and Methods 
S. marcescens, American Type Culture Collection (ATCC 
13880) strain was procured from MicroBioLogics, Inc., USA 
and stored in laboratory conditions for further use. 
Antimicrobials and biochemicals tested against control and 
treated S. marcescens were procured from Sigma-Aldrich 
(MA, USA). The experimental studied parameters were 
estimated with the help of MicroScan Walk-Away
®
 (Dade 
Behring Inc., West Sacramento, CA, USA) using Negative 
Breakpoint Combo 30 (NBPC 30) panel with respect to the 
control group (Gr.).  
2.1. Inoculum Preparation 
The turbidity standard technique using direct inoculation 
of revived and lyophilized strain of S. marcescens was used. 
Using a sterile wooden applicator stick or bacteriological 
loop, the surfaces of 4-5 large or 5-10 small morphologically 
similar cultures were touched for well-isolated colonies from 
an 18-24 hour non-inhibitory agar plate. Further, S. 
marcescens cells were emulsified in 3 mL of inoculum water 
to an equivalent of a 0.5 McFarland barium sulfate turbidity 
standard. 100 µL of the standardized suspension was pipetted 
into 25 mL of inoculum water using pluronic and inverted 8-
10 times. 
2.2. Experimental Design 
The impact of biofield treatment on tested bacterium S. 
marcescens was evaluated in two groups. 
Group I: ATCC strain in lyophilized state was considered 
as control. No treatment was given and analyzed for 
antimicrobial sensitivity, biochemical reactions and biotype 
number as per the standard protocol.  
Group II: The lyophilized state sample of ATCC strain 
was divided into two parts named as Gr. IIA and Gr. IIB. 
Both the groups of ATCC strain of S. marcescens in 
lyophilized state were subjected to Mr. Trivedi’s unique 
biofield treatment. Gr. IIA was analyzed on day 10 for 
antimicrobial sensitivity, biochemical reactions and biotype 
number as per the standard protocol, while Gr. IIB sample 
was stored in lyophilized state for 159 days at -70ºC. Gr. 
IIB was further sub-divided in two separate parts named as 
Gr. IIB - Study I and Gr. IIB - Study II. 
Group IIB - Study I. 
After 159 days, the sample was revived and tested for 
antimicrobial sensitivity, MIC, biochemical reactions and 
biotyping were performed as per the standard protocol.  
Group IIB - Study II. 
The stored strain was revived from -70ºC and again 
provided the Mr. Trivedi’s biofield treatment (re-treatment) 
on day 159. After biofield retreatment, the sample was sub-
cultured into three separate tubes on three different days (Day 
0, Day 5 and Day 10) and analyzed keeping the main treated 
tube aside. Each sample was analyzed after 5 days of its sub-
culturing.  
2.3. Biofield Treatment Strategy 
The lyophilized sample of S. marcescens was subjected to 
Mr. Trivedi’s biofield energy treatment (first treatment) 
which was analyzed on day 10 (Gr. IIA), followed by 
retreatment after storing for 159 days in revived state (Gr. 
IIB, Study II). The first part was considered as control, no 
treatment was given to this part. The treated samples were 
handed over to Mr. Trivedi for biofield energy treatment 
under standard laboratory conditions. Mr. Trivedi provided 
the biofield treatment through his energy transmission 
process, which includes bioenergy emission to second sets of 
samples without touching. After treatment, sample was 
handed over in the same condition and stored at standard 
conditions as per the standard experimental protocol. An 
optimum precautionary measure was taken while evaluating 
the antibiogram analysis throughout the experiments. The 
differences in parameters before and after the treatment were 
noted and compared [21]. 
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2.4. Antimicrobial Susceptibility Test 
Investigation of antimicrobial susceptibility of S. 
marcescens was carried out with the help of automated 
instrument, MicroScan Walk-Away
®
 using NBPC 30 panel. 
The panel can be stored at 2 to -25ºC for analysis. The panel 
was allowed to equilibrate to room temperature prior to 
rehydration. All opened panels were used on the same day. 
The tests carried out on MicroScan were miniaturized of the 
broth dilution susceptibility test that has been dehydrated. 
Briefly, 0.1 mL of the standardized suspension of S. 
marcescens was pipetted into 25 mL of inoculum water using 
pluronic, inverted 8 to 10 times and inoculated, rehydrated, 
and then subjected to incubation for 16 hours at 35°C. 
Rehydration and inoculation were performed using the 
RENOK
®
 system with inoculators-D (B1013-4). 25 mL of 
standardized inoculum suspension was poured into inoculum 
tray. The detailed experimental procedure and conditions 
were followed as per the manufacturer's instructions. The 
antimicrobial susceptibility pattern (S: Susceptible, R: 
Resistant; I: Intermediate, and IB; Inducible β-lactamases) 
and MIC values were determined by observing the lowest 
antimicrobial concentration showing inhibition of growth [21]. 
2.5. Biochemical Reaction Studies 
The biochemical reactions of S. marcescens were 
performed using photometric or fluorogenic reader. On the 
basis of nature of bacilli (Gram-negative or Gram-positive), 
computerized reports were generated using conventional 
panels, which utilizes the photometric reader. Before 
commencing the experiment, the NBPC 30 panel was first 
incubated and read on the MicroScan Walkaway system. 
After evaluating the experimental reading on the Walkaway 
system, the NBPC 30 panel was removed from system and 
recorded on the Biomic system within 1 hour. The instrument 
consists of a database associated with collective information, 
which was required to identify the microbes with respect to 
group, genera, or species of the family. Detailed experimental 
procedure was followed as per manufacturer-recommended 
instructions [21]. 
2.6. Identification of Organism by Biotype Number 
The biotype number of S. marcescens was determined on 
MicroScan Walk-Away
®
 processed panel data report with the 
help of biochemical reactions data [21]. 
3. Results and Discussion 
3.1. Antimicrobial Susceptibility Test 
Antimicrobial sensitivity result and MIC values of tested 
antimicrobials after biofield treatment on S. marcescens are 
summarized in Table 1 and 2, respectively. All the values 
presented are compared with the control group (Gr. I). 
Antimicrobials such as amikacin, cefepime, tobramycin, and 
gentamicin were reported for improved sensitivity i.e. 
resistance (R) in control group to susceptible (S) in all the 
experimental tested groups after biofield treatment on S. 
marcescens. Further, aztreonam, cefotaxime, cefotetan, and 
ceftazidime were reported for improved sensitivity from 
resistance (R) to inducible β-lactamases (IB), while ceftriaxone 
showed alter sensitivity pattern from intermediate (I) to 
inducible β-lactamases (IB) in all the experimental treated 
groups after biofield treatment. Biofield treated S. marcescens 
showed an improved sensitivity pattern of cefoxitin from R to 
IB in all the experimental groups except Gr. II, day 10, as no 
change was observed in Gr. II as compared to the control (Gr 
I). The sensitivity pattern of chloramphenicol was altered and 
reported as R to I in all the experimental treated groups except 
Gr. IIB (study I), day 15. Ticarcillin/k-clavulanate was reported 
with altered sensitivity as IB to I, only in Gr, IIB (Study II), 
day 10 as compared to control. Out of 32 tested antimicrobials, 
12 antimicrobials were reported for altered sensitivity pattern 
after biofield treatment in S. marcescens. Rest of the 
antimicrobials did not report any change in their sensitivity 
pattern after biofield energy treatment. 
Table 1. Effect of biofield treatment on antimicrobial susceptibility pattern of tested antimicrobials against Serratia marcescens. 
S. No. Antimicrobial 
Gr. I Gr. IIA Gr. IIB, Study I Gr. IIB, Study II 
Control Day 10 Day 159 Day + 5 Day + 10 Day + 15 
1 Amikacin R S S S S S 
2 Amoxicillin/k-clavulanate R R R R R R 
3 Ampicillin/sulbactam R R R R R R 
4 Ampicillin R R R R R R 
5 Aztreonam R IB IB IB IB IB 
6 Cefazolin R R R R R R 
7 Cefepime R S S S S S 
8 Cefotaxime R IB IB IB IB IB 
9 Cefotetan R IB IB IB IB IB 
10 Cefoxitin R R IB IB IB IB 
11 Ceftazidime R IB IB IB IB IB 
12 Ceftriaxone I IB IB IB IB IB 
13 Cefuroxime R R R R R R 
14 Cephalothin R R R R R R 
15 Chloramphenicol R I I I I R 
16 Ciprofloxacin S S S S S S 
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S. No. Antimicrobial 
Gr. I Gr. IIA Gr. IIB, Study I Gr. IIB, Study II 
Control Day 10 Day 159 Day + 5 Day + 10 Day + 15 
17 Gatifloxacin S S S S S S 
18 Gentamicin R S S S S S 
19 Imipenem S S S S S S 
20 Levofloxacin S S S S S S 
21 Meropenem S S S S S S 
22 Moxifloxacin S S S S S S 
23 Piperacillin/tazobactam IB IB IB IB IB IB 
24 Piperacillin IB IB IB IB IB IB 
25 Tetracycline R R R R R R 
26 Ticarcillin/k-clavulanate IB IB IB IB I IB 
27 Tobramycin R S S S S S 
28 Trimethoprim/ Sulfamethoxazole S S S S S S 
R: Resistant; I: Intermediate; S: Susceptible; IB: Inducible β-lactamases; Gr: Group. 
Table 2. Minimum inhibitory concentration (MIC) of tested antimicrobials against Serratia marcescens. 
S. No. Antimicrobial 
Gr. I Gr. IIA Gr. IIB, Study I Gr. IIB, Study II 
Control Day 10 Day 159 Day + 5 Day + 10 Day + 15 
1 Amikacin >32 ≤16 ≤16 ≤16 ≤16 ≤16 
2 Amoxicillin/k-clavulanate >16/8 >16/8 >16/8 >16/8 >16/8 >16/8 
3 Ampicillin/sulbactam >16/8 >16/8 >16/8 >16/8 >16/8 >16/8 
4 Ampicillin >16 >16 >16 >16 >16 >16 
5 Aztreonam >16 ≤8 ≤8 ≤8 ≤8 ≤8 
6 Cefazolin >16 >16 >16 >16 >16 >16 
7 Cefepime >16 ≤8 ≤8 ≤8 ≤8 ≤8 
8 Cefotaxime >32 ≤8 ≤8 ≤8 ≤8 ≤8 
9 Cefotetan >32 ≤16 ≤16 ≤16 ≤16 ≤16 
10 Cefoxitin >16 >16 ≤8 ≤8 ≤8 ≤8 
11 Ceftazidime >16 ≤8 ≤8 ≤8 ≤8 ≤8 
12 Ceftriaxone 32 ≤8 ≤8 ≤8 ≤8 ≤8 
13 Cefuroxime >16 >16 >16 >16 >16 >16 
14 Cephalothin >16 >16 >16 >16 >16 >16 
15 Chloramphenicol >16 16 16 16 16 >16 
16 Ciprofloxacin ≤1 ≤1 ≤1 ≤1 ≤1 ≤1 
17 ESBL-a Scrn >4 ≤4 ≤4 ≤4 >4 ≤4 
18 ESBL-b Scrn >1 ≤1 ≤1 ≤1 ≤1 ≤1 
19 Gatifloxacin ≤2 ≤2 ≤2 ≤2 ≤2 ≤2 
20 Gentamicin >8 ≤4 ≤4 ≤4 ≤4 ≤4 
21 Imipenem ≤4 ≤4 ≤4 ≤4 ≤4 ≤4 
22 Levofloxacin ≤2 ≤2 ≤2 ≤2 ≤2 ≤2 
23 Meropenem ≤4 ≤4 ≤4 ≤4 ≤4 ≤4 
24 Moxifloxacin ≤2 ≤2 ≤2 ≤2 ≤2 ≤2 
25 Nitrofurantoin >64 >64 >64 >64 >64 >64 
26 Norfloxacin ≤4 ≤4 ≤4 ≤4 ≤4 ≤4 
27 Piperacillin/tazobactam ≤16 ≤16 ≤16 ≤16 ≤16 ≤16 
28 Piperacillin ≤16 ≤16 ≤16 ≤16 ≤16 ≤16 
29 Tetracycline >8 >8 >8 >8 >8 >8 
30 Ticarcillin/k-clavulanate ≤16 ≤16 ≤16 ≤16 64 ≤16 
31 Tobramycin >8 ≤4 ≤4 ≤4 ≤4 ≤4 
32 Trimethoprim/Sulfamethoxazole ≤2/38 ≤2/38 ≤2/38 ≤2/38 ≤2/38 ≤2/38 
MIC values are presented in µg/mL; Gr.: Group; ESBL-a, b Scrn: Extended spectrum beta-lactamase a, b Screen. 
The MIC results of tested antimicrobials against control 
and biofield treated S. marcescens were presented in Table 
2. About four-fold decrease in MIC value were reported in 
case of cefotaxime (>32 to ≤8 µg/mL) and ceftriaxone (32 
to ≤8 µg/mL) in all the experimental treated groups as 
compared with the control. Approximately, two-fold 
decrease in MIC values were reported in case of amikacin 
and cefotetan (>32 to ≤16 µg/mL), aztreonam, cefepime, 
and ceftazidime (>16 to ≤8 µg/mL), and gentamicin and 
tobramycin (>8 to ≤4 µg/mL) as compared to the control 
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group. The decrease in MIC values of antimicrobial 
cefoxitin (>16 to ≤8 µg/mL) was reported in all the 
experimental treated groups except in Gr. II, on day 10 as 
compared to the control. Biofield treated S. marcescens 
reported with slight decrease in MIC values in case of 
chloramphenicol, except in Gr. IIB, Study II, on day 15. 
Extended-spectrum β-lactamases (ESBL-b Scrn) was 
reported with slight decrease in MIC value in all the treated 
groups, while ESBL-a Scrn also showed slight decrease in 
MIC in all the treated groups except in Gr. IIB, study II, day 
10 as compared with the control. Only ticarcillin/k-
clavulanate was reported with around four-fold increase in 
MIC (≤16 to 64 µg/mL) in Gr. IIB, study II, on day 10 as 
compared to the control, while rest of the groups were 
reported with same MIC value as in control group (Gr. I). 
Out of 32 tested antimicrobials, 14 antimicrobials were 
reported for altered MIC values after biofield treatment in 
S. marcescens as compared to the control. Rest of the 
antimicrobials did not report any change in MIC values 
after biofield treatment. 
Many recent reports analyzed and described the hospital 
outbreaks of S. marcescens [22]. Natural resistance had 
reported in S. marcescens against ampicillin, macrolides, 
and first-generation cephalosporins. Cephalosporins and 
penicillins are the class of antibiotics which are mostly 
reported with resistance against S. marcescens due to 
chromosomal-mediated β-lactamase production. Increasing 
number of clinical isolates of aminoglycoside resistant S. 
marcescens were highly reported [23]. This bacterium plays 
an important role as an opportunistic pathogen among 
immunocompromised hosts [24]. According to the report of 
Craven et al. increasing incidence of amikacin resistance 
among clinical isolates of S. marcescens, could limit the 
usefulness of antibiotic treatment therapy [25]. 
Experimental control results were well supported with 
literature, as natural resistance in amikacin. The biofield 
energy treatment on S. marcescens results an improved 
sensitivity pattern of amikacin, with decreased MIC value 
in all the experimental treated groups. Besides, the 
resistance nature of amikacin was changed to susceptible, 
hence, it could be used as an alternate treatment approach in 
complementary and alternate medicine against S. 
marcescens infections in near future. However, cefepime is 
the preferred drug and useful in patients with nosocomial 
infections caused by aerobic Gram-negative bacilli, even 
effective against microbes, which are resistant to most of 
the third-generation cephalosporins and gentamicin [26, 
27]. Biofield treated S. marcescens results in improved 
antimicrobial sensitivity of cefepime and gentamicin from 
resistant to susceptible, while decreased the MIC value as 
compared to the control. Cefepime is an extended-spectrum 
cephalosporin, it’s extended activity results from its low 
affinity for type I β-lactamase and has the ability to passes 
through porin channels [28]. Biofield energy treatment 
might increase the ability of cefepime to cross the porin 
channel and inhibit the growth of S. marcescens. 
Basic mechanism behind aminoglycosides against 
microbes are, either through the alteration of the cell 
envelop, which prevent drug uptake, or by modifying the 
drug moiety by inactivation enzymes [29]. Gentamicin 
resistance is generally caused by acetyltransferase AAC 
(3)-1, an inactivating enzyme mediated by plasmids [30]. 
Biofield treatment might transfer the energy and inhibits the 
enzyme activities of S. marcescens responsible for 
resistance pattern against gentamicin. Results reported the 
alteration of the sensitivity pattern of gentamicin from 
resistance to susceptible, with decreased MIC values by 
about two-fold in all the experimental treated groups after 
biofield treatment in S. marcescens as compared to the 
control. Similarly, tobramycin an aminoglycosides has been 
reported for its resistance pattern due to the presence of 
combination of aac(6')-Ia, aac(6')-Ic, and aac(6')-Ib genes 
[31]. Biofield energy treatment might act at enzymatic or 
genetic level, which may improve the susceptibility pattern 
and decreased the MIC of tobramycin against S. 
marcescens. 
Studies have been reported by many researchers using 
normal/cancer cells as the target of biofield treatments and 
reported associated intracellular level changes [32]. 
Another study showed an influence on the in-vitro growth 
of bacteria cultures [33]. The experimental design and 
results suggest that an alterations might occur even after 
storage of sample at -70ºC for 159 days. It suggests that Mr. 
Trivedi’s unique biofield energy treatment has the ability to 
alter the antimicrobial sensitivity in treated S. marcescens 
even in the lyophilized storage condition for a long 
duration. Based on the above findings the antimicrobials 
those are resistance now converted into susceptible after 
biofield energy treatment. Antimicrobial interactions with 
S. marcescens might alter the ligand-receptor protein that 
results in different phenotypic characteristics [34]. Our 
research group has also reported significantly improved the 
sensitivity pattern of antibiotics after biofield treatment on 
pathogenic microbes [19, 20], and inhibit the growth of 
cancer cells [35]. The results are very well supported with 
previous published literature. Based on these results, it is 
expected that biofield energy treatment has the scope to be 
an alternative approach beside existing antimicrobial 
therapy in near future. 
3.2. Biochemical Reactions Studies 
Biochemical reactions determine the presence of various 
enzymes which were used in identifying the microorganisms. 
Rapid identification can be accomplished with specific set of 
biochemical tests, which is the most common approach for 
determining the genus and species of an organism. This will 
define the ability of microorganism to grow and survive in 
the presence of certain inhibitors used in various biochemical 
reactions [36]. Results obtained from different set of 
biochemical reactions studies for differentiation of S. 
marcescens after biofield treatment are illustrated in Table 3. 
Experimental results showed negative reaction i.e. (+) 
positive to (-) negative in case of arabinose, arginine, 
hydrogen sulfide, kanamycin, malonate, melibiose, raffinose, 
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rhamnose, tobramycin, and urea in all the experimental 
treated groups as compared with the control group. The 
biochemicals galactosidase and adonitol also showed 
negative reaction only in Gr. IIB, Study II, on day 10, as 
compared to the control. The rest of the tested biochemicals 
did not show any alteration in biochemical reaction with 
respect to the control. Overall, 12 out of 33 tested 
biochemicals (36.36%) were reported for altered biochemical 
reactions pattern as compared to the control. 
Table 3. Effect of biofield treatment on biochemical reactions of Serratia marcescens. 
S. No. Code Biochemical 
Type of Response 
Gr. I Gr. IIA Gr. IIB, Study I Gr. IIB, Study II 
Control Day 10 Day 159 Day + 5 Day + 10 Day + 15 
1 ACE Acetamide - - - - - - 
2 ADO Adonitol + + + + - + 
3 ARA Arabinose + - - - - - 
4 ARG Arginine + - - - - - 
5 CET Cetrimide - - - - - - 
6 CF8 Cephalothin + + + + + + 
7 CIT Citrate + + + + + + 
8 CL4 Colistin + + + + + + 
9 ESC Esculin hydrolysis + + + + + + 
10 FD64 Nitrofurantoin + + + + + + 
11 GLU Glucose + + + + + + 
12 H2S Hydrogen sulfide + - - - - - 
13 IND Indole - - - - - - 
14 INO Inositol - - - - - + 
15 K4 Kanamycin + - - - - - 
16 LYS Lysine + + + + + + 
17 MAL Malonate + - - - - - 
18 MEL Melibiose + - - - - - 
19 NIT Nitrate + + + + + + 
20 OF/G 
Oxidation-
fermentation/glucose 
+ + + + + + 
21 ONPG Galactosidase + + + + - + 
22 ORN Ornithine + + + + + + 
23 OXI Oxidase - - - - - - 
24 P4 Penicillin + + + + + + 
25 RAF Raffinose + - - - - - 
26 RHA Rhamnose + - - - - - 
27 SOR Sorbitol + + + + + + 
28 SUC Sucrose + + + + + + 
29 TAR Tartrate - - - - - - 
30 TDA 
Tryptophan 
deaminase 
- - - - - - 
31 TO4 Tobramycin + - - - - - 
32 URE Urea + - - - - - 
33 VP Voges-Proskauer + + + + + + 
- : negative; +: positive; Gr.: Group. 
Basic biochemical characteristics of S. marcescens 
include negative for indole production, due to the extraction 
of cell pigment into the upper organic layer. Further, S. 
marcescens not only ferments glucose to acid, but it also 
produces gas, which can be observed as bubble in the 
Durham tube, hence give positive reaction in glucose, 
sucrose, and sorbitol. It has the ability to reduce nitrate to 
nitrite, hence nitrate positive test. Lysine, ornithine, Voges-
Proskauer, urea, and citrate are some other characteristics 
positive reactions biochemical test, while indole and 
oxidase are the negative reaction test of S. marcescens. All 
the above biochemical reactions in control group are well 
supported with literature data [37]. 
3.3. Identification of Organism by Biotype Number 
S. marcescens was further identified based on the 
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database associated with collective information of 
conventional biochemical characters. The biotype number 
of particular organism was evaluated after interpreting the 
results of the biochemical reactions. The biotype number 
then led to the particular organism identification. In this 
experiment, biotyping was performed using an automated 
system, and results showed a change in biotype number 
(7020 5356) in Gr. IIA (on day 10), Gr. IIB (Study I, on day 
159), and Gr. IIB (Study II, on day 5 and 15) with red 
pigment as characteristic features as compared to the 
control Gr. I (7736 7376). Gr. IIB, Study II was also 
reported for altered biotype number as 7000 5346, on day 
10 as compared to the control Gr. I (7736 7376) (Table 4) 
with red pigment as characteristic features. The alteration in 
species was not reported in any of the experimental treated 
groups after biofield treatment as compared to the control. 
This change of biotype number may be due to the alteration 
of some enzymatic reactions under the influence of biofield 
energy treatment. Our research group recently reported the 
impact of biofield energy treatment on pathogenic microbes 
that results in altered biotype number [20]. 
Table 4. Effect of biofield treatment on biotype number of Serratia marcescens. 
Feature 
Gr. I Gr. IIA Gr. IIB, Study I Gr. IIB, Study II 
Control Day 10 Day 159 Day + 5 Day + 10 Day + 15 
Biotype number 77367376 (Very rare biotype) 70205356 70205356 70205356 70005346 70205356 
Organism identification S. marcescens S. marcescens S. marcescens S. marcescens S. marcescens S. marcescens 
 
4. Conclusions 
In general, bioenergy healing therapy is an area, often 
neglected by mainstream medicine and research, however it 
may results as a complementary and alternate medicine in 
cost effective manner. Antimicrobial sensitivity results 
reports an improved sensitivity and decreased MIC values 
(two to four fold) of antimicrobials such as amikacin, 
aztreonam, cefepime, cefotaxime, cefotetan, cefoxitin, 
ceftazidime, gentamicin, tobramycin, and chloramphenicol as 
compared to the control. The results suggest some 
enzymatic/genetic alterations which may suppress the 
enzymes responsible for resistance pattern of antimicrobials. 
Additionally, the enzymatic alterations were reported in 
biochemical reaction tests, which showed changes in 12 out 
of 33 tested biochemicals. Further, the biotyping results an 
alteration in the biotype numbers in all the experimental 
treated groups were assessed with respect to the control. 
Thus, it can be concluded that Mr. Trivedi’s unique biofield 
energy treatment could be applied to alter the antimicrobials 
sensitivity pattern, which could be used as an alternate 
treatment approach and as an energy medicine in the near 
future. 
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